Effect of Jiangtangxiaozhi Capsule on intestinal flora in obese IGT patients

Phase 1

• Conditions: Impaired glucose tolerance

• Registration Number: ITMCTR2000003135
• Lead Sponsor: Xiyuan Hospital,China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Aged 18-60 years old;
2. IGT and obesity diagnostic criteria were met;
3. No antibiotics, probiotics and any other Chinese and Western medicine for digestive system diseases were used within 1 month before treatment;
4. There was no history of chronic gastrointestinal disease and hepatobiliary infection;
5. Signed informed consent.

Exclusion Criteria

1. ALT and AST were 1.5 times higher than the upper limit of normal value and creatinine was higher than the upper limit of normal value;
2. TG>5.7mmol/l;
3. Patients with severe circulatory system diseases, respiratory system diseases, immune system diseases, malignant tumors and other serious diseases;

4. Those who have obvious diet preference or single diet habit;
5. Those who take metformin, acarbose and other Western medicine and have the effect of reducing blood sugar;
6. Participants in other clinical trials within 3 months;
7. Mental illness patients;
8. Pregnant or lactating women;
9. Those who are intolerant to jiangtangxiaozhi capsule or simulant.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glucagon like peptide-1;Insulin resistance index;lipopolysaccharide;blood fat;DNA extraction of intestinal flora gene;